A forum for researchers, students and applicants in the field of cyclodextrin technology
Cyclo Therapeutics, Inc., a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and
Therapies targeting neurological conditions such as Alzheimer’s or Parkinson’s diseases are hampered by the presence of the blood-brain barrier (BBB).
CycloLab Cyclodextrin R&D Ltd. proudly announces winning of a national grant about the development of cyclodextrin-dervatives for autophagy-associated neurodegenerative diseases.
Scientific report has published a paper on γ-cyclodextrin-enabled crocetin formulation which can deliver crocetin into the brain. [1] Crocetin (CRT)
Crocetin (CRT) has shown various neuroprotective effects such as antioxidant activities and the inhibition of amyloid β fibril formation, and
Cyclo Therapeutics reported the publication of an international patent application for the treatment of Alzheimer’s disease with HPBCD.
“World Congress on Neuroscience and Brain Disorders” is scheduled to be held from March 30-31, 2020 in Osaka, Japan. The
CTD Holdings, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical
A recent paper in Cell Reports published an interesting finding: polymeric degradation products (compound X and Z, respectively) of antibiotics
CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with
